# Joseph M. Connors

Source: https://onco.cc/people/joseph-connors/  
OnCo record `joseph-connors` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led ECHELON-1, which replaced bleomycin with brentuximab vedotin in first-line advanced Hodgkin lymphoma.

## Summary

Joseph Connors was principal investigator of ECHELON-1, the trial showing brentuximab vedotin plus AVD improves progression-free and later overall survival compared with ABVD in advanced Hodgkin lymphoma, the first change to first-line therapy in decades. He built the BC Cancer lymphoid cancer database and population-based treatment guidelines that document real-world outcomes across all lymphomas.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: hodgkin; adc; canada
- Role: Clinical Professor Emeritus, BC Cancer Centre for Lymphoid Cancer, University of British Columbia
- Specialisms: Hodgkin lymphoma; Population-based lymphoma care; Antibody-drug conjugates; Treatment guidelines

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Connors%20JM%5BAuthor%5D%20Hodgkin%20brentuximab

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/)
- institutions: [BC Cancer](https://onco.cc/institutions/bc-cancer/)
- trials: [ECHELON-1](https://onco.cc/trials/echelon-1/)
- key papers: [ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma](https://onco.cc/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/)

---
JSON: https://onco.cc/api/v1/entities/joseph-connors.json